Diabetes related phenotypes and their influence on outcomes of patients with corona virus disease 2019 (COVID-19)
-
Published:2023-10-16
Issue:1
Volume:15
Page:
-
ISSN:1758-5996
-
Container-title:Diabetology & Metabolic Syndrome
-
language:en
-
Short-container-title:Diabetol Metab Syndr
Author:
Alves Lais Isidoro,Bosco Adriana Aparecida,Rosa Adriana Aparecida,Correia Marcia Regina Soares,Matioli Sergio Russo,da Silva Maria Elizabeth Rossi,Barros-Filho Tarcisio E.P.,Utiyama Edivaldo M.,Segurado Aluisio C.,Perondi Beatriz,Montal Amanda C.,Harima Leila,Fusco Solange R.G.,Silva Marjorie F,Rocha Marcelo C.,Rios Izabel Cristina,Kawano Fabiane Yumi Ogihara,Jesus Maria Amélia de,Kallas Esper,Francisco Maria Cristina Peres Braido,Carmo Carolina Mendes do,Tanaka Clarice,Oliveira Maura Salaroli,Guimarães Thaís,Lázari Carolina dos Santos,Magri Marcello M.C.,Marchini Julio F.M.,Duarte Alberto José da Silva,Sabino Ester C.,Costa Silvia Figueiredo,Morais Anna Miethke,Souza Heraldo Possolo de,Carvalho Carlos Roberto Ribeiro,Ferreira Juliana Carvalho,Levin Anna Sara Shafferman,
Abstract
Abstract
Introduction
Diabetes mellitus (DM) is associated with severe forms of COVID-19 but little is known about the diabetes—related phenotype considering pre-admission, on-admission and data covering the entire hospitalization period.
Methods
We analyzed COVID-19 inpatients (n = 3327) aged 61.2(48.2–71.4) years attended from March to September 2020 in a public hospital.
Results
DM group (n = 1218) differed from Non-DM group (n = 2109) by higher age, body mass index (BMI), systolic blood pressure and lower O2 saturation on admission. Gender, ethnicity and COVID-19-related symptoms were similar. Glucose and several markers of inflammation, tissue injury and organ dysfunction were higher among patients with diabetes: troponin, lactate dehydrogenase, creatine phosphokinase (CPK), C-reactive protein (CRP), lactate, brain natriuretic peptide, urea, creatinine, sodium, potassium but lower albumin levels. Hospital (12 × 11 days) and intensive care unit permanence (10 × 9 days) were similar but DM group needed more vasoactive, anticoagulant and anti-platelet drugs, oxygen therapy, endotracheal intubation and dialysis. Lethality was higher in patients with diabetes (39.3% × 30.7%) and increased with glucose levels and age, in male sex and with BMI < 30 kg/m2 in both groups (obesity paradox). It was lower with previous treatment with ACEi/BRA in both groups. Ethnicity and education level did not result in different outcomes between groups. Higher frequency of comorbidities (hypertension, cardiovascular/renal disease, stroke), of inflammatory (higher leucocyte number, RCP, LDH, troponin) and renal markers (urea, creatinine, potassium levels and lower sodium, magnesium) differentiated lethality risk between patients with and without diabetes.
Conclusions
Comorbidities, inflammatory markers and renal disfunction but not Covid-19-related symptoms, obesity, ethnicity and education level differentiated lethality risk between patients with and without diabetes.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference27 articles.
1. Pelle MC, Zaffina I, Provenzano M, Moirano G, Arturi F. COVID-19 and diabetes-two giants colliding: from pathophysiology to management. Front Endocrinol. 2022;13:974540. 2. Hartmann-Boyce J, Rees K, Perring JC, Kerneis SA, Morris EM, Goyder C, et al. Risks of and from SARS-CoV-2 infection and COVID-19 in people with diabetes: a systematic review of reviews. Diabetes Care. 2021;12:2790–811. 3. Erener S. Diabetes, infection risk and COVID-19. Mol Metab. 2020;39:101044. 4. Govender N, Khaliq OP, Moodley J, Naicker T. Insulin resistance in COVID-19 and diabetes. Prim Care Diabetes. 2021;15:629–34. 5. Schlesinger S, Neuenschwander M, Lang A, Pafili K, Kuss O, Herder C, Roden M. Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis. Diabetologia. 2021;64:1480–91.
|
|